Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.

Spinal muscular atrophy outcome measure physical therapists scoliosis

Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
27 Feb 2024
Historique:
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: aheadofprint

Résumé

Spinal muscular atrophy (SMA) is a neuromuscular disorder characterised by progressive motor function decline. Motor function is assessed using several functional outcome measures including the Revised Hammersmith Scale (RHS). In this study, we present longitudinal trajectories for the RHS in an international cohort of 149 untreated paediatric SMA 2 and 3 patients (across 531 assessments collected between March 2015 and July 2019). We contextualise these trajectories using both the Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM). At baseline, this cohort included 50% females and 15% of patients had undergone spinal fusion surgery. Patient trajectories were modelled using a natural cubic spline with age, sex, and random effects for each patient. RHS and HFMSE scores show similar trends over time in this cohort not receiving disease modifying therapies. The results confirm the strong correlation between the RHS and RULM previously observed in SMA types 2 and 3a. Scoliosis surgery is associated with a reduction of 3 points in the RHS, 4.5 points in the HFMSE for the SMA 2 population, and a reduction of 11.8 points in the RHS, and 13.4 points in the HFMSE for the SMA 3a populations. When comparing the RHS and RULM, there is a lower correlation in the type 3a's than the type 2 patients. In the SMA 2 population, there is no significant difference between the sexes in either the RHS or HFMSE trajectories. There is no significant difference in the RULM trajectory in the SMA 2 or 3a participants by sex. This study demonstrates that the RHS could be used in conjunction with other functional measures such as the RULM to holistically detect SMA disease progression. This will assist with fully understanding changes that occur with treatments, further defining trajectories and therapy outcomes.

Sections du résumé

Background UNASSIGNED
Spinal muscular atrophy (SMA) is a neuromuscular disorder characterised by progressive motor function decline. Motor function is assessed using several functional outcome measures including the Revised Hammersmith Scale (RHS).
Objective UNASSIGNED
In this study, we present longitudinal trajectories for the RHS in an international cohort of 149 untreated paediatric SMA 2 and 3 patients (across 531 assessments collected between March 2015 and July 2019).
Methods UNASSIGNED
We contextualise these trajectories using both the Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM). At baseline, this cohort included 50% females and 15% of patients had undergone spinal fusion surgery. Patient trajectories were modelled using a natural cubic spline with age, sex, and random effects for each patient.
Results UNASSIGNED
RHS and HFMSE scores show similar trends over time in this cohort not receiving disease modifying therapies. The results confirm the strong correlation between the RHS and RULM previously observed in SMA types 2 and 3a. Scoliosis surgery is associated with a reduction of 3 points in the RHS, 4.5 points in the HFMSE for the SMA 2 population, and a reduction of 11.8 points in the RHS, and 13.4 points in the HFMSE for the SMA 3a populations. When comparing the RHS and RULM, there is a lower correlation in the type 3a's than the type 2 patients. In the SMA 2 population, there is no significant difference between the sexes in either the RHS or HFMSE trajectories. There is no significant difference in the RULM trajectory in the SMA 2 or 3a participants by sex.
Conclusions UNASSIGNED
This study demonstrates that the RHS could be used in conjunction with other functional measures such as the RULM to holistically detect SMA disease progression. This will assist with fully understanding changes that occur with treatments, further defining trajectories and therapy outcomes.

Identifiants

pubmed: 38427497
pii: JND230211
doi: 10.3233/JND-230211
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Amy Wolfe (A)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
Evelina London Children's Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Georgia Stimpson (G)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Danielle Ramsey (D)

University of Suffolk, Ipswich, UK.

Giorgia Coratti (G)

Pediatric Neurology Unit, Catholic University, Rome, Italy.
Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Sally Dunaway Young (S)

Stanford University, Palo Alto, USA.

Anna Mayhew (A)

John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Integrated Laboratory Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK.

Marika Pane (M)

Pediatric Neurology Unit, Catholic University, Rome, Italy.
Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Annemarie Rohwer (A)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Robert Muni Lofra (R)

John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Integrated Laboratory Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK.

Tina Duong (T)

Stanford University, Palo Alto, USA.

Emer O'Reilly (E)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Evelin Milev (E)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Matthew Civitello (M)

St. Jude Children's Research Hospital, Memphis, USA.
Nemours Children's Hospital and University of Central Florida College of Medicine, Orlando, USA.

Valeria A Sansone (VA)

The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.

Adele D'Amico (A)

Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Enrico Bertini (E)

Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Sonia Messina (S)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Claudio Bruno (C)

Center of Translational and Experimental Myology and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Istituto Giannina Gaslini and University of Genoa, Genoa, Italy.

Emilio Albamonte (E)

The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.

Elena Mazzone (E)

Pediatric Neurology Unit, Catholic University, Rome, Italy.
Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Marion Main (M)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.

Jacqueline Montes (J)

Columbia University Irving Medical Center, New York, USA.

Allan M Glanzman (AM)

Children's Hospital of Philadelphia, Philadelphia, USA.

Zarazuela Zolkipli-Cunningham (Z)

Children's Hospital of Philadelphia, Philadelphia, USA.
Department of Pediatrics, University of Pennsylvania, PA, USA.

Amy Pasternak (A)

Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Chiara Marini-Bettolo (C)

John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Integrated Laboratory Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK.

John W Day (JW)

Stanford University, Palo Alto, USA.

Basil T Darras (BT)

Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Darryl C De Vivo (DC)

Columbia University Irving Medical Center, New York, USA.

Giovanni Baranello (G)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Mariacristina Scoto (M)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Richard S Finkel (RS)

St. Jude Children's Research Hospital, Memphis, USA.
Nemours Children's Hospital and University of Central Florida College of Medicine, Orlando, USA.

Eugenio Mercuri (E)

Pediatric Neurology Unit, Catholic University, Rome, Italy.
Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Francesco Muntoni (F)

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Classifications MeSH